Preclinical Results on Alnylam’s Novel C16 Conjugate Technology for Delivery of siRNAs to the Central Nervous System Presented at TIDES USA 2022 Meeting

11 May, 2022 Preclinical Results on Alnylam’s Novel C16 Conjugate Technology for Delivery of siRNAs to the Central Nervous System Presented at TIDES USA 2022 Meeting

New results on Alnylam’s platform advancements enabling delivery of therapeutic short interfering RNAs (siRNAs) to the central nervous system (CNS) were presented at the TIDES USA, Oligonucleotide & Peptide Therapeutics 2022 Meeting being held in Boston on May 9-12. Additional preclinical data were presented on Alnylam’s GEMINI platform for simultaneous silencing of two transcripts within the CNS with a single siRNA entity.

Thiel CS., “Recent Advancements for the Delivery of siRNAs to the Central Nervous System”